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Abstract
Background: Platelet depletion is a key feature of hemolytic uremic syndrome (HUS) caused by Shiga toxin-producing
Escherichia coli (STEC) infection. The mechanism underlying STEC-induced platelet depletion, however, is not completely
understood.
Methodology/Principal Findings: Here we demonstrated for the first time that platelet surface expression of CD47 was
significantly decreased in C57BL6 mice treated with concentrated culture filtrates (CCF) from STEC O157:H7. STEC O157:H7
CCF treatment also led to a sharp drop of platelet counts. The reduction of cell surface CD47 was specific for platelets but
not for neutrophil, monocytes and red blood cells. Down-regulation of platelet surface CD47 was also observed in isolated
human platelets treated with O157:H7 CCF. Platelet surface CD47 reduction by O157:H7 CCF could be blocked by anti-TLR4
antibody but not anti-CD62 antibody. Down-regulation of platelet surface CD47 was positively correlated with platelet
activation and phagocytosis by human monocyte-derived macrophages. Furthermore, the enhanced phagocytosis process
of O157:H7 CCF-treated platelets was abolished by addition of soluble CD47 recombinants.
Conclusions/Significance: Our results suggest that platelet CD47 down-regulation may be a novel mechanism underneath
STEC-induced platelet depletion, and that the interactions between CD47 and its receptor, signal regulatory protein a
(SIRPa), play an essential role in modulating platelet homeostasis.
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Introduction
Shiga toxin (Stx)-producing Escherichia coli (STEC) have been
widely reported to be associated with cases of hemolytic uremic
syndrome (HUS) [1,2]. Although thrombocytopenia is a major
feature of HUS, the mechanism by which the platelets are
depleted in HUS is unclear. Previous studies indicated that platelet
activation might be an important factor for thrombocytopenia
since expression of platelet-derived products such as platelet factor
4 [3] and soluble P-selectin [4] were elevated during acute HUS.
The plasma from patients with HUS also increased aggregation of
normal platelets from healthy subjects. As possible causal factor of
HUS, Stx1 and Stx2, are representatives of AB class of bacterial
exotoxins [5]. For example, Stx can directly bind to human
platelets via globotriaosylceramide (Pk antigen) and a novel
platelet glycosphingolipid [6], and such binding may contribute
to platelet activation and microthrombus formation observed in
HUS. The toxin has also been identified in the kidney of HUS
patients [7] and is cytotoxic for renal endothelial and epithelial
cells [8,9]. Moreover, animal models have reproduced aspects of
HUS using wild-type bacteria that produced the toxin [10,11,12]
or purified toxin [13,14]. Culture filtrates from STEC were found
to induce platelet-aggregating activity [15] although the experi-
ments with purified Shiga toxin showed controversial results in
platelet aggregation or P-selection expression [16,17]. HUS-
associated Shiga toxins were found to promote endothelial-cell
secretion and impair ADAMTS13 cleavage of unusually large von
Willebrand factor multimers [18]. Other STEC secreted compo-
nents such as LPS also play a significant role in developing the
aspects of HUS such as platelet activation and thrombocytopenia
[19].
Serving as an integrin-associated protein and a self-recognition
marker [20,21,22,23], CD47 has been implicated in depletion of
apoptotic cells and aging cells [21,24]. Olsson et al [25] previously
showed that platelet homeostasis was modulated by platelet CD47
under both normal condition and passive immune thrombocyto-
penia. The role of interactions between CD47 and its ligand,
signal regulatory protein a (SIRPa), in regulating the clearance of
platelets or other apoptotic cells by macrophages was also reported
previously [26,27,28]. However, the alteration of platelet CD47
expression and its role in STEC infection-induced platelet
depletion remains unclear.
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expression is specifically reduced in mice treated with concentrat-
ed STEC O157:H7-secreted products (CCF) and the effect of
O157:H7 CCF is likely toll like receptor (TLR)-dependent. Down-
regulation of platelet CD47 is positively correlated with an
increase of platelet activation and aggregation, as well as the
phagocytosis of platelets by macrophages.
Materials and Methods
Bacterial Strains and Reagents
EHEC O157:H7 (strain 99G144) was derived from an outbreak
of hemolytic-uremic syndrome (HUS) in Xuzhou, Jiangsu, China
in 1999. Toxin-negative E. coli O157:H19 (strain 99A041) was
used as a control [29]. STEC isolates were serotyped using
antisera against E-coli O antigens 1 to 173 and H antigens 15 to
56. PCR results against four major virulence genes Stx1, Stx2, EaeA
and Hly have demonstrated that strain 99G144 is a Stx2-eaeA-hly
type strain, while strain 99A041 is negative for signs of Stx1, Stx2,
eaeA, and hly virulence genes. The Stx production was tested by
using the Vero cell cytotoxicity assay and a commercial latex
agglutination assay. Rat anti-mouse CD47 affinity purified mAb
(clone miap301) was obtained from BD Biosciences (San Diego,
CA). Anti-human TLR4 and TLR9 antibodies were obtained
from Imgenex (San Diego, CA). Inhibitory mouse anti-human
CD47 mAb (C5D5) was used as previously described [30]. Mouse
Anti-Human CD61 mAb (Clone Y2/51) was obtained from
DAKO (Carpinteria, CA).
Preparation of concentrated culture filtrates (CCF) from
STEC
STEC strains were grown overnight in Tryticase soy broth
(Difco Laboratories, Detroit, MI) at 37uC with shaking (180 rpm),
supernatants were filtered through 0.22 mm pore-diameter filters
(Millipore) [31], and concentrated to 3-fold higher concentration
before used.
Animal procedure
6–8 weeks male C57BL6 mice (Jackson Laboratory, Bar
Harbor, ME) were housed with free access to water and food in
a specific pathogen-free facility. All animal care and handling
procedures were carried out in accordance with the National
Institute of Health’s Guide for the Care and Use of Laboratory
Animals and approved by the Institutional Review Board of
Nanjing University, Nanjing, China. Mice were randomly divided
into three groups. Group 1 (n=6) included control mice (1 ml of
saline was injected intraperitoneally); in group 2 (n=8), 1 ml of
CCF from O157:H7 (strain 99G144) was administered intraper-
itoneally on day 1 and day 2; in group 3 (n=6), 1 ml of CCF from
O157:H19 (strain 99A041) was administered on day 1 and day 2.
All mice were sacrificed on day 4 after blood and urine sampling.
Complete blood count and the measurement of lactic dehydro-
genase (LDH) level were performed. CD47 knockout mice
(CD47
2/2) obtained from Jackson Laboratory served as a control
for CD47 measurement.
Cell isolation and labeling
Isolation and labeling of platelets were done as previously
described [25] with a few modifications. In brief, anticoagula-
tion buffer contained the following: 130 mM trisodium citrate,
10 mMEDTA, 10 mM theophylline, and 2 mg/mL carbacyclin.
Buffered saline glucose citrate (BSGC) contained 110 mM
NaCl, 14 mM trisodium citrate, 10 mM Na2HPO4-7H2O,
2m MK H 2PO2,1m ME D T A ,1 0m Mg l u c o s e ,a n d1mg/
mL carbacyclin, pH 6.8. For mouse platelets, blood was
obtained by cardiac puncture using a syringe containing
anticoagulant buffer. The blood was further diluted to a total
volume of 1.5 mL in BSGC followed by centrifugation (300 g,
3 min). Platelet-rich plasma (PRP) fractions were collected,
combined, and re-suspended in BSGC to a concentration of
5610
8 platelets/mL. Isolated cells were identified as platelets
by labeling with anti-CD41 phycoerythrin (PE)-conjugated
antibody (Immunotech). 2.5 mM CMFDA (Molecular Probes)
was added to the platelets and incubated for 30 minutes at room
temperature. Platelets were then centrifuged (1200 g,1 0m i n )t o
remove the free dye. Human platelets were isolated from
periphery blood of healthy volunteers. The present study was
approved by the Institutional Review Board of Nanjing
University, Nanjing, China. Written informed consent was
obtained from each participant. Human monocytes,neutrophils
(PMNs) and red blood cells (RBCs) were isolated as previously
described [32]. To prepare monocyte-derived macrophages
(MDMs), isolated monocytes were cultured in DMEM/10%
FCS supplemented with macrophage colony-stimulating factor
(M-CSF) for 6 days [33]. Mature macrophages (3610
5/well)
were then plated in 24-well tissue culture plates and allowed to
adhere for 2 h. After removal of non-adherent cells, the cells
were then cultured in DMEM/10% FCS without M-CSF for
24 h before use in phagocytosis assays. All the protocols and
procedures were approved by Nanjing University Research
Ethics Board.
Immunofluorescence labeling and flow cytometric
analysis
Blood was collected from a mouse tail vein and was diluted in
PBS with 5 mM EDTA. Cells were then incubated with rat anti-
CD47 monoclonal antibody (Clone miap301), followed by FITC-
conjugated secondary antibody, and phycoerythrin-conjugated
anti–mouse CD61 for 30 minutes on ice. After washing off
unbound antibody, the samples were analyzed using FACscan flow
cytometry and CellQuest software (BD Biosciences). Platelets were
distinguished, based on the cell size and CD61 expression.
Platelet adhesion
For platelet adhesion, commercial obtained fibrinogen (FBG)
and purified SIRPa-GST chimera were immobilized onto 96-well
plates prior to adhesion assays. SIRPa-GST chimera and GST
protein (served as control) were prepared as previously described
[32]. Fluorescently labeled platelets were then added into plates
and incubated for 1 h at 37uC. After three washes, fluorescence
intensity of each well was measured by a fluorescence plate reader
(Molecular Devise) and cell adhesion was presented as percentage
of total applied cells.
Phagocytosis of platelets by monocyte-derived
macrophages
Platelets were incubated with anti-platelet CD61 antibody for
20 minutes at room temperature for opsonization. The cells were
then washed with HBSS and re-suspended in DMEM/10% FCS.
Platelets (3610
7/per well) were then added, and the plates were
centrifuged at 200 g for 1 min to establish contact between
macrophages and platelets. Following incubation for 30 min at
37uC under 5% CO2, the macrophages were washed three times
with HBSS. To remove non-ingested platelets, the macrophages
were treated with 0.5 mM EDTA and 0.05% trypsin in PBS for
5 min. The ingested platelets by macrophages were analyzed by
FV1000 confocal fluorescence microscope equipped with software
CD47 in Platelet Depletion
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the fraction of macrophages with ingested platelets of the total
number of macrophages analyzed in 6–8 random selected fields.
Data analysis
Statistical analysis was performed by using Student t test for
paired samples. All results are expressed as mean6SD. Values of
p,0.05 were considered statistically significant.
Results
In our previous study, an EHEC O157:H7 (strain 99G144) was
derived from an outbreak of HUS in Xuzhou, Jiangsu Province,
China in 1999. PCR results against four major virulence genes
Stx1, Stx2, eaeA and hly have shown that strain 99G144 is a Stx2-
eaeA-hly type strain [29]. To assess the ability of STEC O157:H7
(strain 99G144) to induce HUS-like syndrome in animal, we
prepared the concentrated culture filtrates (CCF) from culture
medium of EHEC strain 99G144 and Shiga toxin-negative
O157:H19 (strain 99A041) (served as a control), respectively,
and then intraperitoneally injected 0.5 mL/per day of these CCFs
into C57BL6 mice. As shown in Figure 1, mice treated with CCF
of strain 99G144 had a sharp drop of platelet count on day 4 post-
injection compared to mice that injected with saline or strain
99A041 CCF. In addition, significant injure particularly bleeding
in multiple organs including kidney, eye and intestine was
observed in mice treated with the CCF of strain 99G144 (data
not shown). The results implicated that C57BL6 mice treated with
STEC O157:H7 CCF suffered a HUS-like symptom.
We next assessed the expression level of CD47 on the surfaces of
platelets, neutrophils (PMNs), monocytes, and red blood cells
(RBCs), respectively. Surprisingly, we found that, on day 3 post-
injection, strain 99G144 CCF treatment strongly decreased CD47
expression on platelet cell surface measured by FACscan flow
cytometry (Figure 2A). In contrast, CD47 expression levels on the
surfaces of other cell types in mouse circulating blood stream, such
as PMNs, monocytes, and RBCs, were not affected by O157:H7
CCF treatment (Figure 2B). Served as a control, treatment with CCF from Shiga toxin-negative O157:H19 (strain 99A041) did not
affect platelet surface CD47 expression level.
The effect of STEC O157:H7 CCF on platelet surface CD47
expression was further determined using isolated human platelets.
For these experiments, platelets were isolated from periphery
blood of healthy donors, washed with HBSS containing EDTA,
and then incubated with CCF from O157:H7 (strain 99G144) or
O157:H19 (strain 99A041) at 37uC under 5% CO2. As shown in
Figure 3A, platelet surface CD47 expression was reduced by
treatment with strain 99G144 CCF but not strain 99A041 CCF,
implicating that the component(s) in strain 99G144 CCF can
directly interact with platelets and down-regulate platelet CD47
expression. Based on the fact that STEC strain 99G144 is a Stx2-
type strain [29] and we did detect significant amount of stx2 in
CCF of strain 99G144 but not strain 99A041 (data not shown), the
reduction of platelet surface CD47 by STEC strain 99G144 CCF
might be partially due to direct interaction between Stx2 and
platelets. Since it has been reported that toll like receptors (TLRs)
[19] and CD62 [34] were involved in themocypernia induced by
STEC-derived products, we next tested whether TLRs and CD62
play a role in platelet surface CD47 reduction and platelet
depletion induced by STEC strain 99G144 CCF. As shown in
Figure 3B, functional anti-TLR4 antibody strongly blocked the
effects of strain 99G144 CCF on platelet surface CD47 expression
while anti-CD62 antibody showed no effect. Antibody against
TLR9 also reduced the effect of STEC strain 99G144 CCF on
Figure 1. Platelet depletion in C57BL6 mice administered with
concentrated culture filtrates (CCF) of STEC O157:H7 (strain
99G144). Note that platelet number was rapidly decreased in mice
treated with O157:H7 (strain 99G144) CCF (n=8) compared to that in
mice treated with saline (n=6) or CCF from O157:H19 (strain 99A041)
(n=6). *, p,0.05, **, p,0.01.
doi:10.1371/journal.pone.0007131.g001
Figure 2. Reduction of platelet surface CD47 expression in
mice treated with CCF from STEC O157:H7 (strain 99G144). A,
CD47 expression on platelet surfaces measured by flow cytometry. Cells
derived from CD47
2/2 mice served as a negative control in CD47
immunofluorescence labeling and measurement by flow cytometry. B,
CD47 expression levels on the surfaces of platelets (PLT), neutrophils
(PMN), monocytes (MO), and red blood cells (RBC), respectively. Shiga
toxin-negative strain 99A041 (O157:H19) was used as a control for STEC
O157:H7 (strain 99G144). Data were presented as mean6SD of three
independent experiments. *, p,0.05.
doi:10.1371/journal.pone.0007131.g002
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The results implicated that TLR4-mediated signal pathway might
be involved in the modulation of platelet surface CD47 expression
by strain 99G144 CCF treatment. This conclusion was also
supported by directly treating platelets with lipopolysaccharide
(LPS), a TLR4 activating substance [35]. The platelet surface
CD47 expression was significantly decreased by LPS treatment
(Figure 3B).
To examine the functional status of platelets after treatment
with the CCF of STEC O157:H7, isolated human platelets
incubated with or without strain 99G144 CCF were further
allowed to adhere to 96-well tissue culture plates coated with
fibrinogen (FBG) or soluble recombinant of SIRPa extracellular
domain (SIRPa-GST). It has been known when platelets are
activated, there are more platelets adhere to immobilized FBG
[36,37]. As shown in Figure 4A, adhesion of platelets treated with
strain 99G144 CCF to immobilized FBG was significantly higher
than that of non-treated platelets, suggesting that platelets treated
with strain 99G144 CCF were activated. These same platelets
treated with strain 99G144 CCF, however, showed a decreased
adhesion to immobilized SIRPa-GST recombinant compared to
non-treated platelets, confirming that platelets treated with strain
99G144 CCF have less functional SIRPa-binding CD47 on their
surfaces (Figure 4B). Together, these results demonstrate that
platelets treated with strain 99G144 CCF are in activated form
and contain less cell surface CD47.
We next determined the phagocytosis of platelets treated with or
without strain 99G144 CCF by human monocyte-derived
macrophages (MDMs). Platelets were treated with anti-platelet
IgG for opsonization. In separate experiments, incubation was
performed in the presence of inhibitory anti-SIRPa antibody or
soluble CD47 extracellular domain recombinant (CD47-GST). As
shown in Figure 5, after 3 h incubation, phagocytosis of strain
99G144 CCF-treated platelets by MDMs was significantly higher
than that of non-treated platelets or platelets treated with strain
99A041 CCF. In fact, internalization of non-treated platelets by
MDMs was very low. The enhanced uptake of strain 99G144
CCF-treated platelets by MDMs, however, was abolished by
addition of soluble CD47 extracellular domain recombinant.
These results argue that down-regulation of CD47 expression level
on platelet surfaces is positively correlated with platelet depletion
by phagocytes such as macrophages, and that the interactions
between platelet CD47 and macrophage SIRPa play a critical role
in regulating platelet depletion in STEC infection-induced
thrombocytopenia.
Discussion
In the present study, we reported for the first time that platelet
surface CD47 reduction is a critical step of platelet depletion in
STEC-induced HUS. This conclusion was supported by the data
derived from both in vivo and in vitro experiments. First, co-
Figure 3. Reduction of CD47 surface expression level on isolated human platelets by STEC O157:H7 (strain 99G144) CCF. A, strain
99G144 CCF but not O157:H19 CCF decreases CD47 surface expression. B, Reduction of CD47 expression levels by strain 99G144 CCF in the presence
of various antibodies at concentration of 25 mg/ml each. Data were presented as mean6SD of three independent experiments. *, p,0.05.
doi:10.1371/journal.pone.0007131.g003
Figure 4. Down-regulation of platelet surface CD47 expression level positively correlates with activation of platelets. The adhesion of
platelets to immobilized fibrinogen (FBG) (A) and SIRPa extracellular domain recombinant (SIRPa-GST) (B) was measured by an in vitro binding assay.
BSA and GST were used as the controls for FBG and SIRPa-GST in binding assays, respectively. Data were presented as mean6SD of three
independent experiments. *, p,0.05.
doi:10.1371/journal.pone.0007131.g004
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surface CD47 was observed in STEC O157:H7 infected mice.
Reduction of CD47 expression level was likely specific for platelets
since other cells in mouse blood stream had no alteration of
surface CD47 after treatment. Second, we confirmed the effect of
STEC O157:H7 CCF on reduction of platelet surface CD47 and
showed the direct role of STEC strain 99G144 CCF using isolated
human platelets. Furthermore, we found that the reduction of
platelet surface CD47 expression by strain 99G144 CCF could be
blocked by anti-TLRs antibodies, implicating that TLRs-mediated
signal downstream might play a significant role in regulating the
interactions of platelets with the virulent components of STEC
strain 99G144. Third, employing in vitro binding assay, we
showed that the platelets treated with secreted products from
STEC O157:H7 (STEC strain 99G144) were in active condition
(Figure 4A) and contained less functional ligand-binding CD47 on
the surface (Figure 4B). Finally, we demonstrated that activated
platelets after STEC O157:H7 CCF treatment could be rapidly
removed by macrophages through phagocytosis, and that the
phagocytosis of platelets by macrophages could be blocked by
soluble CD47 extracellular domain recombinant (Fig. 5). These
results suggest that the binding interaction between CD47 and its
cellular liagnd, signal regulatory protein a (SIRPa), serves as a
critical negative regulator for platelet depletion by phagocytes such
as macrophages.
Previous studies have shown that Shiga toxins producing
Escherichia coli are the main cause of the hemolytic uremic
syndrome [10,11,12,38]. However, although our data implicated
that Shiga toxins might directly interact with platelets and play a
role in platelet surface CD47 reduction, the exact components in
STEC strain 99G144 CCF that affect platelet CD47 expression
remain unclear. Besides Stx2, LPS might also be the candidates in
down-regulating platelet cell surface CD47 expression. It also
remains unknown why infection by STEC O157:H7 (strain
99G144) selectively reduces platelet surface CD47 expression but
not other circulating cells such as monocytes, neutrophils and red
blood cells. The possible reason underneath this specific platelet
CD47 reduction may be that platelets express unknown receptor(s)
for virulent factors such as Stx2 or LPS.
In summary, our results indicate that CD47 is a critical
molecule that negatively regulates STEC-induced activation and
depletion of platelets. Down-regulation of CD47 level on platelet
surfaces by virulent factors of STEC O157:H7 is likely through
TLRs-mediated signaling pathway. CD47 down-regulation on
platelet surfaces results in a loss of the negative regulatory
mechanism initiated by CD47-SIRPa interactions [21], which in
turn, leads to platelet activation and consequent phagocytosis of
platelets by macrophages or other SIRPa-positive immune cells.
Since soluble CD47 extracellular domain recombinant can block
the enhanced phagocytosis of STEC virulent factors-treated
platelets by macrophages, CD47 may be a novel therapeutic
targets aiming at attenuating and preventing STEC infection-
induced platelet depletion.
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